Orion
41.63 EUR +0.46%13,764 investors are following this company
Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.
P/E (24e)
20.55
EV/EBIT (adj.) (24e)
16.48
P/B (24e)
6.18
Dividend yield-% (24e)
3.96 %
Target price
44.00 EUR
Recommendation
Accumulate
Updated
1.7.2024
NASDAQ Helsinki
ORNBV
Daily low / high price
41.16 / 42.48
EUR
Market cap
5.88B EUR
Turnover
13.22M EUR
Volume
316K
Business risk
Valuation risk
Current
Previous
Analyst
Antti Siltanen
Analyst
Latest videos
Financial calendar
Interim report
08.08.2024
Half year dividend
15.10.2024
Interim report
29.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Ilmarinen Mutual Pension Insurance Company | 3.7 % | 5.2 % |
Erkki Etola and companies | 2.0 % | 6.5 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Mikael Silvennoinen | 15.11.2023 | 44,782EUR |
Mikael Silvennoinen | 15.11.2023 | 27,034EUR |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 1,078.1 | 1,041.1 | 1,340.6 | 1,189.6 | 1,432.5 | 1,447.7 | 1,577.6 | 1,704.7 |
growth-% | 2.6 % | -3.4 % | 28.8 % | -11.3 % | 20.4 % | 1.1 % | 9.0 % | 8.1 % |
EBITDA | 336.5 | 289.0 | 486.6 | 326.4 | 410.3 | 355.3 | 428.2 | 493.5 |
EBIT (adj.) | 280.1 | 243.3 | 439.6 | 274.9 | 361.8 | 311.3 | 378.6 | 443.2 |
EBIT | 280.1 | 243.3 | 439.6 | 274.9 | 361.8 | 311.3 | 378.6 | 443.2 |
Profit before taxes | 278.3 | 242.3 | 440.3 | 271.9 | 359.8 | 307.0 | 374.9 | 440.0 |
Net income | 219.9 | 193.8 | 349.5 | 216.8 | 284.6 | 242.5 | 296.2 | 347.6 |
EPS (adj.) | 1.57 | 1.38 | 2.49 | 1.54 | 2.03 | 1.73 | 2.11 | 2.47 |
growth-% | 9.9 % | -11.9 % | 80.3 % | -38.0 % | 31.3 % | -14.8 % | 22.1 % | 17.4 % |
Dividend | 1.50 | 1.50 | 1.60 | 1.62 | 1.65 | 1.70 | 1.75 | 1.80 |
Dividend ratio | 95.8 % | 108.7 % | 64.3 % | 105.0 % | 81.4 % | 98.5 % | 83.0 % | 72.7 % |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | 31.2 % | 27.8 % | 36.3 % | 27.4 % | 28.6 % | 24.5 % | 27.1 % | 28.9 % |
EBIT-% (adj.) | 26.0 % | 23.4 % | 32.8 % | 23.1 % | 25.3 % | 21.5 % | 24.0 % | 26.0 % |
EBIT-% | 26.0 % | 23.4 % | 32.8 % | 23.1 % | 25.3 % | 21.5 % | 24.0 % | 26.0 % |
ROE | 29.1 % | 26.8 % | 43.1 % | 24.1 % | 31.0 % | 25.5 % | 30.0 % | 32.6 % |
ROI | 34.4 % | 29.5 % | 45.6 % | 24.9 % | 31.7 % | 26.5 % | 32.0 % | 35.9 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 37.53 | 36.52 | 51.24 | 39.27 | 41.63 | 41.63 | 41.63 | 41.63 |
Shares | 140.5 | 140.5 | 140.5 | 140.5 | 140.5 | 140.5 | 140.5 | 140.5 |
Market cap | 5,271.6 | 5,129.7 | 7,197.3 | 5,516.0 | 5,847.5 | 5,847.5 | 5,847.5 | 5,847.5 |
Enterprise value | 5,085.8 | 4,940.3 | 7,078.7 | 5,609.3 | 5,962.9 | 5,918.5 | 5,899.2 | 5,841.4 |
EV/S | 4.7 | 4.7 | 5.3 | 4.7 | 4.2 | 4.1 | 3.7 | 3.4 |
EV/EBITDA | 15.1 | 17.1 | 14.5 | 17.2 | 14.5 | 16.7 | 13.8 | 11.8 |
EV/EBIT (adj.) | 18.2 | 20.3 | 16.1 | 20.4 | 16.5 | 19.0 | 15.6 | 13.2 |
EV/EBIT | 18.2 | 20.3 | 16.1 | 20.4 | 16.5 | 19.0 | 15.6 | 13.2 |
P/E (adj.) | 24.0 | 26.5 | 20.6 | 25.4 | 20.5 | 24.1 | 19.7 | 16.8 |
P/E | 24.0 | 26.5 | 20.6 | 25.4 | 20.5 | 24.1 | 19.7 | 16.8 |
P/B | 7.2 | 7.2 | 7.9 | 6.2 | 6.2 | 6.1 | 5.8 | 5.2 |
P/S | 4.9 | 4.9 | 5.4 | 4.6 | 4.1 | 4.0 | 3.7 | 3.4 |
Dividend yield | 4.0 % | 4.1 % | 3.1 % | 4.1 % | 4.0 % | 4.1 % | 4.2 % | 4.3 % |
Equity ratio | 65.6 % | 66.0 % | 60.4 % | 61.9 % | 60.8 % | 62.7 % | 63.9 % | 67.6 % |
Gearing ratio | -25.4 % | -26.5 % | -13.1 % | 10.5 % | 12.2 % | 7.4 % | 5.1 % | -0.5 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 277.9 | 289.6 | 301.0 | 321.1 | 1,189.6 | 308.5 | 323.9 | 374.6 | 425.5 |
EBITDA | 67.7 | 59.4 | 92.7 | 106.6 | 326.4 | 67.0 | 75.0 | 132.4 | 135.9 |
EBIT | 55.5 | 46.6 | 79.9 | 92.9 | 274.9 | 56.0 | 62.5 | 119.9 | 123.4 |
Profit before taxes | 55.1 | 45.8 | 78.5 | 92.5 | 271.9 | 54.9 | 62.2 | 119.6 | 123.1 |
Net income | 43.8 | 36.4 | 61.4 | 75.2 | 216.8 | 43.7 | 49.2 | 94.5 | 97.2 |
ShowingAll content types
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Orion is developing the Finnish life science industry in a unique collaboration project
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools